Active Pharmaceutical Ingredient API News and Research

RSS

Savient second-quarter net loss decreases to $5.0 million

Savient Pharmaceuticals, Inc. reported financial results for the three and six months ended June 30, 2010. The net loss for the second quarter of 2010 was $5.0 million, or $0.07 per basic and diluted share, on total revenues of $1.0 million, compared with a net loss of $54.8 million, or $0.92 per basic and diluted share on total revenues of $0.7 million for the second quarter of 2009.

4 Aug 2010

Arena reports lower net loss of $28.80M for second-quarter 2010

Arena Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010, and recent developments, including the successful Pre-Approval Inspection, or PAI, of the company's Swiss drug product manufacturing facility by the US Food and Drug Administration, or FDA.

4 Aug 2010

Aptuit announces strategic partnership Siena Biotech

Aptuit, Inc., and Siena Biotech S.p.A., today announced a strategic partnership in which Siena Biotech will take a minority stake in Aptuit's Italian operations in Verona, Italy, and Aptuit will become a provider of choice for Siena Biotech's development pipeline. Under the agreement Aptuit and Siena Biotech will work collaboratively on the development of Siena Biotech's pipeline of compounds, focused in three key therapeutic areas, including Alzheimer's disease, Huntington's disease and oncology.

29 Jul 2010

Clinical Pharmacokinetics Research Laboratory deploys AB SCIEX mass spectrometry technology

AB SCIEX, a global leader in life science analytical technologies, today announced that the Clinical Pharmacokinetics Research Laboratory at the University of Rhode Island's College of Pharmacy is using AB SCIEX mass spectrometry technology to develop a novel test that would enable clinical researchers to use saliva to monitor immunosuppressant drugs commonly administered to make organ transplants successful.

28 Jul 2010

Aphios awarded US patent for compositions, methods for treating diseases involving 5-α reductase enzyme

Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.

28 Jul 2010

Teva second-quarter net sales increase 12% to $3.8 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended June 30, 2010.

27 Jul 2010

Pharma industry leaders reduce R&D time, costs with aspenONE Process Development software

Aspen Technology, Inc., a leading provider of software and services to the process industries, today announced that GlaxoSmithKline, AstraZeneca and other pharmaceutical industry leaders are reducing their research and development time and costs using newly patented technology that is part of AspenTech's aspenONE Process Development for Pharmaceuticals software.

19 Jul 2010

Mylan declares quarterly dividend of $16.25 per share

Mylan Inc. today announced that in accordance with its 2.139 million preferred stock issuance, the company has declared its quarterly dividend of $16.25 per share (based on the annual dividend rate of 6.5% and a liquidation preference of $1,000.00 per share) payable on Aug. 16, 2010, to holders of preferred stock of record as of Aug. 1, 2010.

19 Jul 2010

Apicore announces successful conclusion of Somerset API manufacturing plant's FDA inspection

Apicore LLC announced today that the U.S. Food and Drug Administration (FDA) completed an inspection of its API manufacturing plant in Somerset, New Jersey on July 13, 2010.

17 Jul 2010

Practice Fusion API Challenge kicked off

Practice Fusion, the free, web-based Electronic Health Record company, kicked off the Practice Fusion API Challenge today as part of the Health 2.0 Developer Challenge, an initiative supported by the US Department of Health and Human Services. The challenge invites developers to connect patient health data from medical devices, mobile apps, social media systems and websites to doctors in real-time through Practice Fusion's new API.

15 Jul 2010

Brand-Nu Laboratories adds Chlophedianol Hydrochloride to API line

Brand-Nu Laboratories, a leading US-based high purity chemical manufacturer and distributor, has introduced Chlophedianol Hydrochloride, also known as Clofedanol Hydrochloride JP, to its product portfolio of active pharmaceutical ingredients (APIs).

12 Jul 2010

Apicore files DMF for Fondaparinux Sodium API with U.S. FDA

Apicore LLC announced today that they filed a drug master file (DMF) for Fondaparinux Sodium active pharmaceutical ingredient (API) with the U.S. Food and Drug Administration (FDA) on June 28, 2010.

7 Jul 2010

Aptuit to acquire GSK's research business in Verona

GlaxoSmithKline (GSK) and Aptuit, Inc. announced today that they have finalized an agreement for Aptuit to acquire operations at GSK's Medicines Research Centre in Verona, Italy. The arrangement, which is effective as of July 1, 2010, provides for ongoing employment of the staff at the centre and for Aptuit to supply GSK with R&D services from the facilities. Financial terms have not been disclosed.

1 Jul 2010

Best practices issued to help hospitals manage challenging repercussions of healthcare reform legislation

API Healthcare, the leader in healthcare-specific workforce management solutions, today issued a set of best practices to help hospitals of all sizes effectively prepare for and manage the challenging repercussions of healthcare reform legislation. Industry experts expect this legislation to generate millions of new patients, create a severe nursing shortage and have a significant financial impact on hospitals and other healthcare providers.

1 Jul 2010

Raptor partners with Uni Pharma to commercialize Convivia in Taiwan

Raptor Pharmaceutical Corp., announced that it has entered into an exclusive agreement with Uni Pharma Co., Ltd. to commercialize Convivia™, Raptor's proprietary oral formulation of 4-methylpyrazole, in Taiwan.

30 Jun 2010

World's leading pharma services industry events to held at Frankfurt in 2011

Leading events organiser UBM International Media today announced that its flagship CPhI Worldwide tradeshow will return to Frankfurt, Germany for 2011. Along with co-hosted events - P-MEC Europe for equipment, machinery and technology; ICSE for contract services and packaging; and BioPh Europe for the biopharma sector - the world's leading pharma services industry events will be held at Messe Frankfurt, from Tuesday 25 to Thursday 27 October.

28 Jun 2010

Mylan granted final FDA approval for Procardia XL Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Nifedipine Extended-release Tablets USP, 30 mg, 60 mg and 90 mg, the generic version of Pfizer's Procardia XL® Tablets, a treatment for angina and/or hypertension.

25 Jun 2010

Zilog launches ZMOTION Detection and Control solutions

Zilog, an IXYS company, and a trusted supplier of application specific, embedded micro controller (MCU) system-on-chip (SoC) solutions for industrial and consumer markets, today introduced its latest sensing and control technology for motion detection applications, including intrusion, security alarm industry, customer sensing and lighting control, medical patient monitoring, and other energy management applications.

24 Jun 2010

Ricerca announces services under U.S. DEA license

Ricerca Biosciences, an industry-leading, integrated preclinical contract research organization (CRO) providing services to the chemical and biopharmaceutical industries, is pleased to announce services it can now provide under its United States Drug Enforcement Administration (DEA) license.

18 Jun 2010

AMRI announces acquisition of Hyaluron

AMRI today announced the acquisition of Hyaluron Inc., expanding AMRI's contract manufacturing capabilities to include cGMP manufacturing and sterile filling of parenteral drugs to the biopharmaceutical industry. AMRI has acquired all facilities and equipment as well as a highly trained and experienced staff of professionals with expertise in sterile GMP manufacturing. Purchase price, including debt, was approximately $27 million.

15 Jun 2010